News & Events - Page 2 of 19 - Charcot-Marie-Tooth UK

Pharnext intends to prepare registration and marketing authorizationdossiers for PXT3003, its drug candidate in Charcot-Marie-Tooth diseasetype 1A

20/12/23

Research

Charcot Marie Tooth

Pharnext intends to prepare registration and marketing authorizationdossiers for PXT3003, its drug candidate in Charcot-Marie-Tooth diseasetype 1A

Pharnext reports topline results from the pivotal Phase III clinical trial(PREMIER trial) of PXT3003 in Charcot-Marie-Tooth disease type 1A

20/12/23

Research

Charcot Marie Tooth

Pharnext reports topline results from the pivotal Phase III clinical trial(PREMIER trial) of PXT3003 in Charcot-Marie-Tooth disease type 1A

30/10/23

Awareness Month

Charcot Marie Tooth

Messages of Support for CMT Awareness Month

Pharnext enters the final stretch for the signature of a licensingagreement for its drug candidate in Charcot-Marie-Tooth disease type 1A(PXT3003), enabling it to capitalize on its assets and put an end to theOCEANE-BSA financing line

20/09/23

Research

Charcot Marie Tooth

Pharnext enters the final stretch for the signature of a licensingagreement for its drug candidate in Charcot-Marie-Tooth disease type 1A(PXT3003), enabling it to capitalize on its assets and put an end to theOCEANE-BSA financing line

19/09/23

Awareness Month

Charcot Marie Tooth

CMT Awareness Month: October 2023

Every year during October, we increase our activities to spread the word as widely as possible throughout the UK about our charity and the condition of Charcot-Marie-Tooth. Please click here to find out what we have planned and how you can get involved.

19/09/23

Membership

Charcot Marie Tooth

Membership Reimagined

CMTUK: Membership Reimagined: Q&A We hope our letter above sets out clearly the decision to move from a subscription-based membership […]

Pharnext intends to prepare registration and marketing authorizationdossiers for PXT3003, its drug candidate in Charcot-Marie-Tooth diseasetype 1A

Pharnext reports topline results from the pivotal Phase III clinical trial(PREMIER trial) of PXT3003 in Charcot-Marie-Tooth disease type 1A

Messages of Support for CMT Awareness Month

Pharnext enters the final stretch for the signature of a licensingagreement for its drug candidate in Charcot-Marie-Tooth disease type 1A(PXT3003), enabling it to capitalize on its assets and put an end to theOCEANE-BSA financing line

CMT Awareness Month: October 2023

Membership Reimagined

Connect with us

Login